Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Int J Cancer · 2025 · PMC11887017 · PMID 39707595

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The respective pivotal phase III studies PALOMA‐2, MONALEESA‐2, and MONARCH‐3 showed nearly identical and highly significant results regarding median progression‐free survival (PFS): palbociclib 27.6 months (95% CI 22.1, NA), HR 0.563 (95% CI 0.461, 0.687), 2 , 3 ribociclib 25.3 months (95% CI 23.0, 30.3), HR 0.568 (95% CI 0.457, 0.704), 4 , 5 abemaciclib 28.18 months (HR 0.540 [0.418, 0.698]). 6 With

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.